Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination.

Mengesha, Bethlehem; Asenov, Asen G.; Hirsh-Raccah, Bruria; Amir, Offer; Pappo, Orit; Asleh, Rabea

Vaccination with mRNA vaccines against coronavirus disease 2019 (COVID-19) has been associated with a risk of developing myocarditis and pericarditis, with an estimated standardized incidence ratio of myocarditis being 5.34 (95% CI, 4.48 to 6.40) as compared to the expected incidence based on historical data according to a large national study in Israel. Most cases of myocarditis in vaccine recipients occur in young males, particularly following the second dose, and the presentation is usually mild. Recently, the third (booster) dose has been shown to reduce confirmed infections and severe illness even against common variants of the virus. In Israel, over 4.4 million citizens (more than 45% of the population) have been vaccinated with the third dose of Pfizer-BioNTech vaccine BNT162b2. Herein, we report the first case of a histologically confirmed severe myocarditis following the third dose of BNT162b2 COVID-19 vaccine.

ISRAEL; PERICARDITIS; COVID-19 vaccines; COVID-19; MYOCARDITIS; BOOSTER vaccines; MESSENGER RNA

Vaccines, 2022, Vol 10, Issue 4, pN.PAG

2076-393X

Academic Journal

10.3390/vaccines10040575